New Stock News | New Lotus Flower Plans for Hong Kong IPO Has Been Accepted by the China Securities Regulatory Commission

On April 18, the China Securities Regulatory Commission released the table of domestic companies overseas issuance of securities and listing record (initial public offering and full circulation) (as of April 18, 2025). Among them, Sichuan Xinhua Chinese Herbal Medicine Co., Ltd. (referred to as Xinhua) plans to IPO in Hong Kong and has received materials accepted by the China Securities Regulatory Commission. The prospectus shows that Xinhua is one of China's leading and largest suppliers of Chinese herbal medicine products. Based on the revenue of Chinese herbal medicine products in 2023, the company ranks 2nd in China and is the fastest-growing among the top five market participants, with a compound annual growth rate of 27% from 2022 to 2024. The company provides high-quality Chinese medicine products to customers under the "Xinhua" brand. Since its establishment, the company's business focus has been mainly on Chinese herbal medicine products. With its experience in Chinese herbal medicine products and the sales network accumulated for hospitals, clinics, and pharmacies, the company strategically expands its business to the retail market with new revenue growth points.